bet体育(365·China官网)正规-APP下载IOS

Ribo and Pheiron enter strategic collaboration for AI-assisted drug development of RNA therapeutics

Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase Ⅰ Clinical Data At ESC Congress 2024

Ribo Presents First-In-Class FXI Targeting siRNA Drug RBD4059 Phase Ⅰ Clinical Data At ESC Congress 2024

Innovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNA

Innovating for a Healthier Tomorrow: Ribo Role in Transforming Liver Disease Treatment with siRNA.

Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases

Boehringer Ingelheim partners with Ribo to develop new treatments for people with liver diseases

Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9

Ribo and Qilu Announce Licensing Agreement for siRNA Therapeutic Targeting PCSK9